Pharma News

SCHOTT AG, a global pioneer in manufacturing pharmaceutical glass and packaging, has announced the launch of a new glass tank in its Indian manufacturing plant at Jambusar, Gujarat. The German technology group is further growing its production capacity through this new tank facility with a total investment of more than 20 million euros. The invest comes at a time when the company is celebrating 20 years of operations in India.

Amgen and Oxford Nanopore Technologies Ltd. announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology.

R.C. Patel Institute of Pharmaceutical College and Research, Shirpur organized One day National Conference on “A Global Perspective on Pharmaceutical IPR: Challenges and Potential” on 8th September 2018.

The Seminar was sponsored by Kavayitri Bahinabai Chaudhari North Maharashtra University, Jalgaon. Deliberation witnessed participation of more than 300 delegates comprising of research scholars, under graduate, post graduate students and faculty members from various pharmacy institutes.

EMA is hosting a workshop on Wednesday, 24 October to gather insight from stakeholders on the key areas in human medicines to be covered in its ‘Regulatory Science Strategy to 2025’, a proposed new high-level plan for advancing its engagement with regulatory science.

U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Priority Review for IMBRUVICA®(ibrutinib) in combination with obinutuzumab (GAZYVA®) in previously untreated adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). If the sNDA is approved, the use of IMBRUVICA with obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for the first-line treatment of CLL/SLL. IMBRUVICA is currently FDA-approved to treat adults with CLL/SLL as a single-agent for all lines of therapy and in combination with bendamustine and rituximab (BR).

Virginity testing — a gynecological examination conducted under the belief that it determines whether a woman or girl has had vaginal intercourse — must end, says UN Human Rights, UN Women and the World Health Organization (WHO).

As part of the Administration’s ongoing efforts to strengthen cybersecurity in health care, the U.S. Food and Drug Administration and the U.S. Department of Homeland Security (DHS) announced a memorandum of agreement to implement a new framework for greater coordination and cooperation between the two agencies for addressing cybersecurity in medical devices.

Eleven heads of the world’s leading health and development organizations today signed a landmark commitment to find new ways of working together to accelerate progress towards achieving the United Nations’ Sustainable Development Goals.

The FDA continues to advance new policies, modernize programs and advance opportunities for developing more targeted therapies. Using new technology platforms such as cell and gene therapies and small molecule drugs that target the genomic basis of disease, there are more opportunities to intervene in the underlying mechanisms that cause a disease, and potentially arrest and even reverse its progress.

A  report published today by the European Medicines Agency (EMA) shows that the overall sales of veterinary antimicrobials across Europe have decreased by more than 20% between 2011 and 2016. This continues the downward trend seen over the last few years and confirms that European Union (EU) guidance and national campaigns promoting prudent use of antibiotics in animals to fight antimicrobial resistance are having a positive effect.